Alexander M. Menzies
Experienced in Granulomatous Hypophysitis

Alexander M. Menzies

Mater And Royal North Shore Hospitals
Sydney, NSW, AU 
Experienced in Granulomatous Hypophysitis
Mater And Royal North Shore Hospitals
Sydney, NSW, AU 
OverviewLocationsClinical Research

Overview

Alexander Menzies practices in Sydney, Australia. Mr. Menzies is rated as an Experienced expert by MediFind in the treatment of Granulomatous Hypophysitis. His top areas of expertise are Melanoma, Metastatic Brain Tumor, Lung Metastases, and Brain Tumor.

His clinical research consists of co-authoring 327 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Granulomatous Hypophysitis.

Gender
Male

Locations

Mater and Royal North Shore Hospitals
Sydney, NSW, Australia
Other Locations
40 Rocklands Rds, Wollstonecraft, NSW 2065, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Enrollment Status: Unknown
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Pembrolizumab
Study Phase: Phase 2
A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma
A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma
Enrollment Status: Terminated
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drugs: Tigilanol Tiglate, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

327 Total Publications

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Journal: Journal of neuro-oncology
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Menzies's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile